Bausch + Lomb announced that one of its affiliates has completed the purchase of the Blink® product line of eye and contact lens drops from Johnson & Johnson Vision. This strategic acquisition reflects the company's commitment to enhancing over-the-counter (OTC) consumer convenience in the field of eye care.
The company made the acquisition with $106.5 million in cash, utilizing available funds.
“There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” said John Ferris, executive vice president, Consumer, Bausch + Lomb. “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”
According to a Gallup Study conducted in 2022, 57% of American adults experience eye dryness, and nearly half of them rely on OTC lubricant drops for relief. The incidence of dry eyes is rising, largely due to increased digital device usage. Additionally, contact lens wearers in the United States, estimated at 45 million, are affected by contact lens discomfort and dryness.
The Blink portfolio of eye drops consists of a variety of eye drops and contact lens rewetting drops that provide immediate and long-lasting symptom relief. The products that are part of the acquisition include the following:
● Blink® Tears Lubricating Eye Drops;
● Blink® Tears Preservative Free Lubricating Eye Drops;
● Blink GelTears® Lubricating Eye Drops;
● Blink® Triple Care Lubricating Eye Drops;
● Blink Contacts® Lubricating Eye Drops; and
● Blink-N-Clean® Lens Drops.
More information about Blink eye drops can be found at www.justblink.com.
*Stay in the loop and make sure not to miss real-time breaking news about ophthalmology. Join our community by subscribing to OBN newsletter now.